Todd Zavodnick, Dermavant CEO

Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

Al­most a year to the day af­ter Der­ma­vant Sci­ences land­ed its first FDA ap­proval for plaque pso­ri­a­sis for Vta­ma, the drug­mak­er is out with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.